On August 28, 2026, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved a supplement for Mounjaro (tirzepatide injection, NDA 215866) adding a cardiovascular risk-reduction indication. Lilly’s U.S. prescribing information, revised August 2026 and posted on Lilly’s USPI site, now lists two section 1 bullets: glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and reduction of major adverse cardiovascular (CV) events in adults with type 2 diabetes who are at high risk for these events. DailyMed and openFDA still serve the July 29, 2026 glycemic-only SPL.
For pharmacy and therapeutics (P&T) committees, health plan medical directors, Medicare Part D plan sponsors, and endocrinology access teams, this approval fundamentally shifts the competitive cardiometabolic landscape against semaglutide (Ozempic) and dulaglutide (Trulicity). However, translating this regulatory milestone into formulary tiers and prior authorization (PA) criteria requires understanding the exact evidentiary structure of the pivotal trial:
Did SURPASS-CVOT establish superiority over active comparator Trulicity, does this new claim automatically apply to Zepbound, and can health plans immediately update automated prior authorization criteria based on current DailyMed SPL records?
The direct operational answers establish critical boundaries for payer policy:
- SURPASS-CVOT established noninferiority, not superiority. The trial compared tirzepatide with dulaglutide (Trulicity 1.5 mg once weekly), not placebo. Lilly’s August 2026 USPI Table 10 reports MACE-3 in 803/6,647 (12.1%) Mounjaro-treated versus 863/6,647 (13.0%) dulaglutide-treated participants; hazard ratio 0.92 with a 95.3% CI of 0.83 to 1.01. Noninferiority was met (p=0.007). Superiority to dulaglutide was not established.
- Section 1 says “high risk”; section 14.6 enrolled established CV disease. The labeled indication is adults with type 2 diabetes at high risk for CV death, non-fatal MI, or non-fatal stroke. The supporting trial randomized 13,299 patients with type 2 diabetes and established CV disease. Do not copy Trulicity’s “established CVD or multiple risk factors” sentence or Ozempic’s established-CVD-only PA without reading both section 1 and 14.6.
- The claim is on Mounjaro (NDA 215866), not Zepbound. Zepbound (NDA 217806) remains labeled for chronic weight management and OSA. SURMOUNT-MMO (NCT05556512) is active, not recruiting, and excludes diabetes.
- DailyMed lags the USPI. As of August 30, 2026, live DailyMed/openFDA SPLs (including Lilly setid
d2d7da5d-ad07-4228-955f-cf7e355c8cc0and repackager setid0818426a-53eb-4db7-9609-bbae1e7a3964, effective_time20260729) still list only glycemic control. Drugs@FDA’s latest indexed Efficacy AP remains SUPPL 39 dated 20251219. ePA rules that scrape DailyMed will miss the August label until that index moves. - Existing coverage guides require updates. Pages that still say Mounjaro has no CV claim—including our Mounjaro glycemic coverage guide, the Ozempic versus Mounjaro indication table, and the Mounjaro versus Zepbound brand split—are update targets, not duplicates of this dated supplement.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ MOUNJARO SURPASS-CVOT CARDIOVASCULAR REGULATORY SCORECARD │
├──────────────────────────┬───────────────────────────────────────────────────────────────────────┤
│ Dimension / Metric │ Labeled Fact / Evidentiary Status │
├──────────────────────────┼───────────────────────────────────────────────────────────────────────┤
│ FDA Action Date │ August 28, 2026 (Lilly announcement); USPI Revised 08/2026 │
│ Sponsor Announcement │ Eli Lilly and Company (IR / PR Newswire Release 302862415) │
│ Labeled CV indication │ Section 1: T2D adults at high risk for CV death, non-fatal MI, stroke │
│ Pivotal Trial │ SURPASS-CVOT (NCT04255433); section 14.6; Phase 3 event-driven CVOT │
│ Trial Design │ Active-controlled, randomized, double-blind noninferiority trial │
│ Active Comparator │ Dulaglutide (Trulicity) 1.5 mg once weekly │
│ Trial Scope & Duration │ 13,299 randomized; 640 sites / 30 countries (Lilly); median 210.1 wks │
│ Table 10 analysis set │ 6,647 randomized-and-treated per arm │
│ Primary Endpoint │ Time to first MACE-3 (CV death, MI, or stroke) │
│ Table 10 MACE-3 │ 803/6,647 (12.1%) vs 863/6,647 (13.0%); HR 0.92 (95.3% CI 0.83, 1.01) │
│ Statistical Conclusion │ Noninferiority p=0.007; superiority not established │
│ Enrolled population │ Adults ≥40 with T2D and established CV disease (section 14.6) │
│ Brand Scope │ Mounjaro NDA 215866 only; Zepbound NDA 217806 has no CV claim │
│ SPL & Indexing Status │ Lilly USPI 08/2026 posted; DailyMed/openFDA still 20260729 glycemic │
└──────────────────────────┴───────────────────────────────────────────────────────────────────────┘
What Did FDA Add to Mounjaro NDA 215866 on August 28 vs. Zepbound?
Understanding the precise scope of the August 28 regulatory action requires separating the molecule (tirzepatide) from its distinct commercial brand applications under the Food, Drug, and Cosmetic Act.
The Dual-Brand Indication Split
Eli Lilly markets tirzepatide under two separate New Drug Applications:
- Mounjaro (NDA 215866): Approved on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, later expanded to pediatric patients aged 10 years and older. The August 2026 USPI adds a section 1 indication to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction, and non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. Recent major changes also add a diabetic-retinopathy monitoring warning dated 08/2026.
- Zepbound (NDA 217806): Approved on November 8, 2023, for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities, and subsequently expanded for moderate-to-severe obstructive sleep apnea (OSA).
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ TIRZEPATIDE DUAL-NDA REGULATORY INDICATION BOUNDARY │
├───────────────────────┬───────────────────────────────────┬──────────────────────────────────────┤
│ Regulatory Element │ Mounjaro (NDA 215866) │ Zepbound (NDA 217806) │
├───────────────────────┼───────────────────────────────────┼──────────────────────────────────────┤
│ Approved Indications │ 1. Glycemic control in T2D (≥10y) │ 1. Chronic weight management │
│ │ 2. MACE risk reduction in adults │ (BMI ≥30 or ≥27 with comorbidity) │
│ │ with T2D at high risk for │ 2. Obstructive sleep apnea (OSA) │
│ │ these events (section 1) │ │
├───────────────────────┼───────────────────────────────────┼──────────────────────────────────────┤
│ Underlying CV Trial │ SURPASS-CVOT (NCT04255433) │ SURMOUNT-MMO (NCT05556512) │
│ │ Active-controlled vs Trulicity │ Placebo-controlled in obesity (w/o │
│ │ Status: COMPLETED; USPI 14.6 │ diabetes); ACTIVE_NOT_RECRUITING │
├───────────────────────┼───────────────────────────────────┼──────────────────────────────────────┤
│ Medicare Part D Rule │ Covered under statutory Part D │ Excluded under Social Security Act │
│ │ diabetes benefit; eligible for │ § 1860D-2(e)(2)(A) for weight loss; │
│ │ CV risk-reduction step edits │ limited coverage for OSA indication │
└───────────────────────┴───────────────────────────────────┴──────────────────────────────────────┘
Health plan utilization management (UM) programs must not cross-apply Mounjaro's cardiovascular claim to Zepbound prior-authorization policies. Under Medicare Part D statutory guidelines (Section 1860D-2(e)(2)(A) of the Social Security Act), anti-obesity medications prescribed for weight loss remain excluded from standard Part D coverage. While Wegovy established a pathway for Part D coverage in non-diabetic overweight/obese patients with established CVD under the SELECT trial label expansion, Zepbound cannot obtain that coverage pathway until its dedicated obesity CVOT—SURMOUNT-MMO—is completed, submitted, and approved.
Why Is SURPASS-CVOT an Active-Control Noninferiority Trial vs. Trulicity?
The clinical evidence underpinning Mounjaro's cardiovascular label represents a watershed design choice in metabolic drug development:
1. Active Comparator Design vs. Placebo
Since the FDA issued its landmark 2008 guidance on evaluating cardiovascular risk in new antidiabetic therapies, the vast majority of cardiovascular outcome trials (CVOTs)—including LEADER (liraglutide), SUSTAIN-6 (Ozempic/semaglutide), EMPA-REG OUTCOME (empagliflozin), and DECLARE-TIMI 58 (dapagliflozin)—were structured as placebo-controlled superiority or noninferiority trials on top of background antidiabetic therapy and guideline-directed medical management.
In SURPASS-CVOT (NCT04255433), Lilly randomized 13,299 participants head-to-head against an active GLP-1 receptor agonist comparator: dulaglutide (Trulicity 1.5 mg once weekly). Trulicity was chosen because it had already demonstrated a statistically significant 12% reduction in MACE-3 versus placebo in the REWIND trial (HR 0.88; 95% CI: 0.79, 0.99; p=0.026).
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ CARDIOMETABOLIC CVOT TRIAL DESIGN & STATISTICAL COMPARISON │
├─────────────────────┬───────────────────┬──────────────────────┬─────────────────────────────────┤
│ Trial / Drug │ Comparator │ Enrolled Population │ Primary Outcome & Hazard Ratio │
├─────────────────────┼───────────────────┼──────────────────────┼─────────────────────────────────┤
│ SURPASS-CVOT │ Active Control: │ T2D + Established │ HR 0.92 (95.3% CI: 0.83, 1.01) │
│ Mounjaro │ Trulicity 1.5 mg │ CV disease (Age ≥40) │ Table 10: 12.1% vs 13.0% │
│ (NCT04255433) │ (N = 13,299 rand.)│ Section 14.6 │ Noninferiority p=0.007; │
│ │ │ │ superiority not established │
├─────────────────────┼───────────────────┼──────────────────────┼─────────────────────────────────┤
│ SUSTAIN-6 │ Placebo Control │ T2D + Established │ HR 0.74 (95% CI: 0.58, 0.95) │
│ Ozempic │ (N = 3,297) │ CVD or High Risk │ Superiority Met vs. Placebo │
│ (NCT01720446) │ │ (Age ≥50y) │ (p = 0.02) │
├─────────────────────┼───────────────────┼──────────────────────┼─────────────────────────────────┤
│ REWIND │ Placebo Control │ T2D + Established │ HR 0.88 (95% CI: 0.79, 0.99) │
│ Trulicity │ (N = 9,901) │ CVD OR Multiple Risk │ Superiority Met vs. Placebo │
│ (NCT01394952) │ │ Factors (Age ≥50y) │ (p = 0.026) │
├─────────────────────┼───────────────────┼──────────────────────┼─────────────────────────────────┤
│ SELECT │ Placebo Control │ Overweight/Obesity │ HR 0.80 (95% CI: 0.72, 0.90) │
│ Wegovy │ (N = 17,604) │ + Established CVD │ Superiority Met vs. Placebo │
│ (NCT03574597) │ │ WITHOUT Diabetes │ (p < 0.001) │
└─────────────────────┴───────────────────┴──────────────────────┴─────────────────────────────────┘
2. Interpreting the Statistical Readout
Lilly’s August 2026 USPI section 14.6 and Table 10 are the labeled U.S. numbers (peer-reviewed results were also published as Nicholls SJ et al., N Engl J Med 2025;393:2409-2420, doi:10.1056/NEJMoa2505928):
- Follow-up: Median 210.1 weeks.
- Analysis set: Table 10 uses 6,647 randomized-and-treated participants per arm. The USPI and Lilly press state 13,299 patients were randomized.
- MACE-3: 803 (12.1%) with Mounjaro versus 863 (13.0%) with dulaglutide; HR 0.92 (95.3% CI 0.83, 1.01).
- Hypothesis testing: Noninferiority of Mounjaro to dulaglutide, p=0.007. Superiority was not established. Do not use the ACC journal-scan p-values (0.003 / 0.09) in a dossier.
Lilly’s “8% lower rate of MACE compared to Trulicity” language matches 1 − 0.92. Because the upper 95.3% confidence limit is 1.01, that point estimate is not a labeled superiority claim.
3. Table 10 Components and the Multiplicity Footnote
Table 10 also reports component and all-cause death counts. Footnote (d) states those rows are not controlled for family-wise type I error:
- CV death: 367 (5.5%) vs 409 (6.2%); HR 0.89 (0.77, 1.02)
- Non-fatal MI: 292 (4.4%) vs 310 (4.7%); HR 0.93 (0.80, 1.09)
- Non-fatal stroke: 215 (3.2%) vs 221 (3.3%); HR 0.97 (0.80, 1.16)
- All-cause death: 567 (8.5%) vs 670 (10.1%); HR 0.84 (0.75, 0.94)
The all-cause death interval excludes 1.0, but it is not a multiplicity-controlled labeled claim. USPI 14.6 also notes reductions from baseline in HbA1c and body weight at Month 36 for both arms. Do not convert those observations into a new indication.
DailyMed and openFDA SPL Lag: Managing the P&T Transition
A critical governance challenge during the immediate post-approval window is managing automated electronic prior authorization (ePA) rules when federal labeling repositories lag press announcements.
┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│ REGULATORY REPOSITORY SYNCHRONIZATION AUDIT │
├───────────────────────┬───────────────────────────────┬──────────────────────────────────────────┤
│ Federal Database │ Current Status (2026-08-30) │ Operational Impact on Payer Operations │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ DailyMed / openFDA │ Effective Time: 20260729 │ Indexed SPL still glycemic-only; │
│ SPL Index │ Lilly setid d2d7da5d-... and │ ePA that reads DailyMed will miss the │
│ │ repackager 0818426a-... │ August 2026 section 1 / Table 10. │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ Drugs@FDA Submissions │ Latest Efficacy Action: │ Supplement approval letter and review │
│ (NDA 215866) │ SUPPL 39 (20251219, Ped) │ package not yet posted in DAF index. │
│ │ Last Updated: 2026-08-28 │ P&T must rely on sponsor action packet. │
├───────────────────────┼───────────────────────────────┼──────────────────────────────────────────┤
│ ClinicalTrials.gov │ Status: COMPLETED │ Trial operational parameters verified: │
│ (NCT04255433) │ Actual Enrollment: 13,299 │ Start 2020-05-29; Completion 2025-06-12; │
│ │ Primary Completion: 2025-06-12│ MACE-3 primary outcome through week 259. │
└───────────────────────┴───────────────────────────────┴──────────────────────────────────────────┘
Operational Guidance for P&T Committees
- Use the Lilly USPI now; treat DailyMed as lagging: The August 2026 USPI is posted at Lilly’s labeling site. DailyMed/openFDA have not caught up. Draft medical policy from section 1 and Table 10, not from the July 29 SPL.
- Do not copy-forward Ozempic or Trulicity PA language blindly: Section 1 is “high risk for these events.” Section 14.6 enrolled established CV disease (baseline CAD 65%, prior MI 47%, PAD 25%, prior stroke 19%). Trulicity’s labeled population still includes multiple risk factors without a prior event.
- Document from the trial description, not invented stenosis cutoffs: Use the USPI 14.6 baseline CV-disease list rather than unofficial ABI or percent-stenosis shortcuts.
Comparison with Trulicity REWIND and Ozempic SUSTAIN-6 Indications
When structuring prior-authorization criteria, medical directors must distinguish between secondary prevention (established ASCVD) and primary prevention (multiple cardiovascular risk factors):
1. The REWIND Primary Prevention Difference
Trulicity's FDA-approved cardiovascular indication covers adults with type 2 diabetes mellitus who have established cardiovascular disease OR multiple cardiovascular risk factors. In REWIND, only 31.5% of participants had established CVD at baseline, while 68.5% had cardiovascular risk factors without prior events.
In contrast, SURPASS-CVOT enrolled patients with established CV disease. USPI 14.6 does not report a REWIND-style primary-prevention subgroup. A plan that treats Mounjaro’s section 1 “high risk” sentence as equivalent to Trulicity’s multiple-risk-factor claim is reading past the trial that actually supports the supplement.
2. Ozempic's Dual MACE and CKD Claims
Novo Nordisk's Ozempic (semaglutide injection) carries two distinct outcome-level indications in its FDA label:
- Reduction in the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (supported by SUSTAIN-6).
- Reduction in the risk of kidney disease progression, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (supported by the FLOW trial).
While Mounjaro now has a labeled MACE indication in type 2 diabetes, Ozempic retains a separate CKD-progression claim supported by FLOW. Tirzepatide’s TREASURE-CKD program (NCT05536804) is an active, not-recruiting Phase 2 mechanistic kidney study in overweight/obesity with CKD, with or without type 2 diabetes—not a FLOW-class renal outcomes trial and not a substitute for a labeled CKD indication.
Formulary Economics and Commercial Rebate Strategy
The addition of a cardiovascular risk reduction indication to Mounjaro fundamentally alters the contracting dynamics between Eli Lilly, pharmacy benefit managers (PBMs), and commercial plan sponsors:
1. Parity and Step-Therapy Arguments
Prior to this approval, some commercial and Medicare Advantage formularies treated Ozempic as the preferred incretin when cardiovascular disease was the coverage rationale. SURPASS-CVOT noninferiority and the new section 1 bullet remove the “no CV label” basis for excluding Mounjaro. They do not require any plan to prefer Mounjaro, erase step therapy, or treat a CI that includes 1.01 as a superiority result versus Trulicity. Net-price and rebate negotiations remain plan-specific; this article does not rank manufacturers.
2. Net-Cost Competition
Lilly (Mounjaro) and Novo Nordisk (Ozempic) already compete on T2D formularies. A new MACE indication is one more contracting input. Closed formularies may still choose exclusive preferred status or dual preferred status; that is a rebate decision, not a labeled-superiority conclusion.
Impact on Existing PharmaDossier Portfolios and Coverage Guides
The August 28 approval of Mounjaro's cardiovascular indication directly affects several existing analyses across our biopharma coverage portfolio:
- In our Mounjaro glycemic coverage guide, the indication summary and formulary review framework will be updated to reflect the new section 1 MACE bullet once DailyMed catches the August 2026 USPI.
- In our Ozempic versus Mounjaro indication table, comparison cells previously indicating that Mounjaro possessed no outcomes-level cardiovascular claim will be revised to document SURPASS-CVOT noninferiority.
- In our Mounjaro versus Zepbound brand split, the regulatory boundary separating glycemic/CV access from weight-loss coverage will be updated to reflect Mounjaro's dual glycemic-CV label.
- For context on Trulicity's established formulary positioning and REWIND evidence base, see our Trulicity REWIND coverage guide.
- For an overview of Medicare Part D formulary rules, low-income subsidy thresholds, and weight-loss statutory exclusions, see our Medicare Part D GLP-1 coverage policy.
- For broader corporate strategy and metabolic franchise lifecycle planning, consult our Lilly diabetes-obesity portfolio dossier.
Frequently Asked Questions
Did SURPASS-CVOT prove Mounjaro is superior to Trulicity for MACE?
No. SURPASS-CVOT was an active-controlled noninferiority trial versus dulaglutide 1.5 mg. USPI Table 10 reports MACE-3 in 803/6,647 (12.1%) versus 863/6,647 (13.0%) participants; HR 0.92 (95.3% CI 0.83, 1.01). Noninferiority was met (p=0.007). Superiority to dulaglutide was not established.
Does the August 28 approval give Zepbound a cardiovascular indication?
No. The labeled CV indication is on Mounjaro NDA 215866. Section 1 covers adults with type 2 diabetes at high risk for CV events; section 14.6 describes SURPASS-CVOT in established CV disease. Zepbound (NDA 217806) remains labeled for chronic weight management and OSA. SURMOUNT-MMO (NCT05556512) is active, not recruiting, and excludes diabetes.
Is the current DailyMed Mounjaro SPL the August 28 CV label?
No. As of August 30, 2026, DailyMed and openFDA still index the July 29, 2026 (20260729) glycemic-only SPL. Lilly’s USPI revised August 2026 already contains section 1 and Table 10. Use that document until DailyMed’s effective_time moves.
Should the May 15 Mounjaro coverage guide be a new article or an update?
The May 15 coverage guide remains our baseline guide for Mounjaro glycemic coverage. As documented in our editorial roadmap, that guide and related comparison tables are designated for targeted updates to reflect the August 28 labeled indication delta rather than redundant republication.
Sources
- Eli Lilly and Company: MOUNJARO (tirzepatide) injection Prescribing Information. Revised August 2026. Section 1; section 14.6; Table 10. https://uspl.lilly.com/mounjaro/mounjaro.html?s=pi
- Eli Lilly and Company: FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Investor Relations Press Release. Issued August 28, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular
- PR Newswire / Eli Lilly: FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. PR Newswire Release 302862415. Published August 28, 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html
- ClinicalTrials.gov / NLM: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). Identifier: NCT04255433. Retrieved August 30, 2026. https://clinicaltrials.gov/study/NCT04255433
- ClinicalTrials.gov / NLM: A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). Identifier: NCT05556512. https://clinicaltrials.gov/study/NCT05556512
- ClinicalTrials.gov / NLM: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD). Identifier: NCT05536804. Phase 2. https://clinicaltrials.gov/study/NCT05536804
- New England Journal of Medicine: Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025;393:2409-2420. doi:10.1056/NEJMoa2505928. https://www.nejm.org/doi/full/10.1056/NEJMoa2505928
- The Lancet: Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121-130. https://pubmed.ncbi.nlm.nih.gov/31189511/
- U.S. National Library of Medicine / DailyMed: MOUNJARO search results (manufacturer setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0 and repackager setid 0818426a-53eb-4db7-9609-bbae1e7a3964). Effective time 20260729 as retrieved August 30, 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=MOUNJARO
- U.S. Food and Drug Administration / Drugs@FDA: Application Tracking – NDA 215866 (MOUNJARO). Latest indexed Efficacy AP still SUPPL 39 dated 20251219 as of openFDA last_updated 2026-08-28. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
- U.S. Food and Drug Administration: OZEMPIC (semaglutide injection) Labeling Supplement 209637s025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
